Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study
JNCI: Journal of the National Cancer Institute · 2024
DOI: 10.1093/jnci/djae062 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Danielle Novetsky Friedman und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Cancer Survivors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Center Support, American Lebanese Syrian Associated Charities.
Abstract (Originalsprache)
Background
Early efforts at risk-adapted therapy for neuroblastoma are predicted to result in differential late effects; the magnitude of these differences has not been well described.
Methods
Late mortality, subsequent malignant neoplasms (SMNs), and severe/life-threatening chronic health conditions (CHCs), graded according to CTCAE v4.03, were assessed among 5-year Childhood Cancer Survivor Study (CCSS) survivors of neuroblastoma diagnosed 1987-1999. Using age, stage at diagnosis, and treatment, survivors were classified into risk groups (low [n = 425]; intermediate [n = 252]; high [n = 245]). Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) of SMNs were compared with matched population controls. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals for CHC compared with 1029 CCSS siblings.
Results
Among survivors (49.8% male; median age = 21 years, range = 7-42; median follow-up = 19.3 years, range = 5-29.9), 80% with low-risk disease were treated with surgery alone, whereas 79.1% with high-risk disease received surgery, radiation, chemotherapy ± autologous stem cell transplant (ASCT). All-cause mortality was elevated across risk groups (SMRhigh = 27.7 [21.4-35.8]; SMRintermediate = 3.3 [1.7-6.5]; SMRlow = 2.8 [1.7-4.8]). SMN risk was increased among high- and intermediate-risk survivors (SIRhigh = 28.0 [18.5-42.3]; SIRintermediate = 3.7 [1.2-11.3]) but did not differ from the US population for survivors of low-risk disease. Compared with siblings, survivors had an increased risk of grade 3-5 CHCs, particularly among those with high-risk disease (HRhigh = 16.1 [11.2-23.2]; HRintermediate = 6.3 [3.8-10.5]; HRlow = 1.8 [1.1-3.1]).
Conclusion
Survivors of high-risk disease treated in the early days of risk stratification carry a markedly elevated burden of late recurrence, SMN, and organ-related multimorbidity, whereas survivors of low/intermediate-risk disease have a modest risk of late adverse outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pediatrics, Weill Cornell Medical College, New York, NY, USA.
- Public Health Science Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Pediatrics, The Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Pediatrics, The University of Chicago, Chicago, IL, USA.
ORCID-Profile: Danielle Novetsky Friedman, Emily S Tonorezos
Förderung
- NCI NIH HHS
- Cancer Center Support
- American Lebanese Syrian Associated Charities
- St Jude Children's Research Hospital
- National Institute of Health
- National Cancer Institute
- St Jude Children’s Research Hospital
Zitieren
APA
Friedman, D. N., Goodman, P. J., Leisenring, W. M., Diller, L. R., Cohn, S. L., Howell, R. M., Smith, S. A., Tonorezos, E. S., Wolden, S. L., Neglia, J. P., Ness, K. K., Gibson, T. M., Nathan, P. C., Turcotte, L. M., Weil, B. R., Robison, L. L., Oeffinger, K. C., Armstrong, G. T., Sklar, C. A., & Henderson, T. O. (2024). Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae062
Vancouver
Friedman DN, Goodman PJ, Leisenring WM, Diller LR, Cohn SL, Howell RM, et al. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae062
BibTeX
@article{Friedman2024,
author = {Friedman, Danielle Novetsky and Goodman, Pamela J and Leisenring, Wendy M and Diller, Lisa R and Cohn, Susan L and Howell, Rebecca M and Smith, Susan A and Tonorezos, Emily S and Wolden, Suzanne L and Neglia, Joseph P and Ness, Kirsten K and Gibson, Todd M and Nathan, Paul C and Turcotte, Lucie M and Weil, Brent R and Robison, Leslie L and Oeffinger, Kevin C and Armstrong, Gregory T and Sklar, Charles A and Henderson, Tara O},
title = {Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
doi = {10.1093/jnci/djae062}
}
EUVIMED